Treatment Options for Protease Inhibitor-exposed Children

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that switching to a regimen based on efavirenz will be as effective and safe as remaining on a regimen based on Lopinavir/ritonavir for HIV-infected children.

The investigators propose an unblinded randomized clinical trial to evaluate a simplification, protease-inhibitor (PI)-sparing treatment strategy among nevirapine (NVP)-exposed HIV-infected children treated initially with lopinavir/ritonavir (LPV/r). HIV-infected children aged 3-5 years, who have a history of exposure to NVP as part of prevention of mother-to-child HIV transmission (PMTCT), initiated LPV/r-based therapy in the first 36 months of life or who were enrolled on the control arm of Neverest 2 and who are virally suppressed with a viral load \< 50 copies/ml will be included. These children will be randomized to either substitute efavirenz (EFV) for LPV/r or to continue on their LPV/r-based regimen. Eight weeks prior to the primary randomization, eligible children will also be randomized to either remain on stavudine (D4T) or switch to abacavir (ABC). Children will be followed with regular viral load and other clinical tests for 48 weeks after the primary randomization. Children in the experimental arm who have breakthrough viremia (-defined as two subsequent viral loads \> 1000 copies/ml) on the EFV-based regimen will reinitiate the LPV/r regimen. The primary objective is to test whether the durability of viral suppression is equivalent when children are switched to EFV-based therapy. The primary study endpoint is failure to have HIV RNA \< 50 copies/ml and/or confirmed viremia \>1000 copies/ml. Secondary aims include comparison of immune preservation, toxicities, selection of resistance mutations, and adherence across the two arms. Antiretroviral drug concentrations and adherence will be investigated as possible explanations for the success and/or failure of this simplification regimen. The overall goal of the study is to contribute to the evidence base to allow expansion of treatment options for HIV-infected children in low resource settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

NCT00273975

HIV Infections

COMPLETED PHASE2

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058

HIV Infections

COMPLETED PHASE1/PHASE2

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

NCT00001091

HIV Infections

COMPLETED PHASE1

Pediatric Expanded Access Program-Oral Solution (0831-908)

NCT00543530

HIV Infections

COMPLETED PHASE3

Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

NCT00364793

HIV Infections

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Lopinavir/ritonavir (LPV/r)

Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m\^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m\^2 or 2 tablets twice per day if body surface area was 0.9m\^2 or higher.

Group Type ACTIVE_COMPARATOR

Lopinavir/ritonavir (LPV/r)

Intervention Type DRUG

Children are assigned to stay on their current LPV/r-based antiretroviral regimen.

Group 2: Efavirenz (EFV)

Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.

Group Type EXPERIMENTAL

Efavirenz (EFV)

Intervention Type DRUG

Children are assigned to begin a EFV-based antiretroviral based regimen.

Group D: Stavudine (D4T)

Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily

Group Type ACTIVE_COMPARATOR

Stavudine (D4T)

Intervention Type DRUG

Children are assigned to stay on their current antiretroviral regimen which includes D4T.

Group A: Abacavir (ABC)

Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.

Group Type EXPERIMENTAL

Abacavir (ABC)

Intervention Type DRUG

Children stop taking D4T and switch to ABC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Efavirenz (EFV)

Children are assigned to begin a EFV-based antiretroviral based regimen.

Intervention Type DRUG

Lopinavir/ritonavir (LPV/r)

Children are assigned to stay on their current LPV/r-based antiretroviral regimen.

Intervention Type DRUG

Stavudine (D4T)

Children are assigned to stay on their current antiretroviral regimen which includes D4T.

Intervention Type DRUG

Abacavir (ABC)

Children stop taking D4T and switch to ABC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
* Reliable history or documented exposure to NVP used as part of PMTCT
* Initiated antiretroviral therapy with LPV/r at age less than 36 months
* Receiving LPV/r-based ART for at least 12 months
* At least one viral load measurement less than 50 copies/ml conducted as part of screening for the study
* ALT measurement grade I or less (DAIDS Toxicity Tables 2004) (Appendix A). These may be repeated until ALTs normalize if necessary.

Exclusion Criteria

* Prior treatment with any NNRTI drug as part of a therapeutic regimen
* Substitution of other NRTI drugs (instead of 3TC and D4T which are the standard first line regimen) will be allowed.

Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No